Leukemia  >>  mocravimod (KRP-203)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
mocravimod (KRP-203) / Priothera
MO-TRANS, NCT05429632: Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Recruiting
3
249
Europe, Japan, US, RoW
mocravimod
Priothera SAS
Adult Acute Myeloid Leukemia
11/25
11/25
2021-002864-36: A phase IIb placebo-controlled efficacy and safety study of mocravimod in AML patients undergoing HSCT

Not yet recruiting
2/3
249
Europe
mocravimod, KRP203, 1.0 mg, Capsule, hard
Priothera S.A.S., Priothera SAS, Priothera S.A.S.
Patients undergoing allogeneic hematopoietic stem cell transplant (HSCT) for acute myeloid leukemia (AML), Patients undergoing allogeneic hematopoietic stem cell transplant (HSCT) for acute myeloid leukemia (AML), Diseases [C] - Immune System Diseases [C20]
 
 

Download Options